Targeted Therapies in Non Small Cell Lung Cancer
 

Post Test

A score of 70% must be achieved to receive continuing education credits.
 
1. Taking an EGFR inhibitor for Non-Small Cell Lung cancer (NSCLC) has given some patients drastic results in just five days.
  True
   False
2. Targeted therapies may provide the next great advance in cancer treatment.
  True
   False
3. One of the hallmarks of cancer is that it has limited replicative potential.
 True
 False
4. A recurring theme in cancer (including EGFR) is that the developmental pathways that are important to a growing fetus or embryo become reactivated and run amok.
   True
   False
5. A goal of customized therapy is to find that particular pathway and turn it off so that cancer cells are no longer addicted to specific pathways.
 True
 False
6. Massive tumor lysis is not a concern in tumors that are treated with chemotherapy.
   True
   False
7. The eventual goal with cancer treatment is to treat only those patients who are the most likely to benefit from therapy and the least likely to experience toxicity.
True
 False
8. Bevacizumab is a VEGF inhibitor that has been studied in combination with chemotherapy in NSCLC and has been shown to lead to a modest increase in one-year survival.
 True
  b. False
9. Patients who have mutations respond better to chemotherapy than taking an EGFR inhibitor.
   True
   False
10. Knowing the cancer’s biology is very important in deciding which agents will be effective in treatment.
  True
   False


Targeted Therapies in Non Small Cell Lung Cancer

Activity evaluation and improvement process:
Please rate this activity on the following scale:
4 - Excellent        3 - Good        2 - Fair        1 - Poor
1.Based on the content presented I am better able to:  
  • Identify advanced targeted therapy treatment regimens for patients with non small-cell lung cancer
    4        3        2        1
  • Describe how targeted and traditional therapies for NSCLC can be integrated
    4        3        2        1
  • Discuss how to incorporate the latest clinical trial data on targeted therapies into clinical practice
    4        3        2        1
  • Review newly released NCCN Guidelines for lung cancer
   4        3        2        1
  • Apply evidence-based guidelines to formulate targeted therapy treatment strategies for patients with late-stage NSCLC
   4        3        2        1
  • Describe risk factors to consider in selecting the appropriate molecular-targeted agents for patients with advanced NSCLC
   4        3        2        1
2. Activity met my expectations   4        3        2        1  
3. Activity was free of bias   4        3        2        1
4. Activity content was understandable   4        3        2        1
5. Presenter was free of bias   4        3        2        1
6. Method of learning was beneficial   4        3        2        1
7. Presenter covered material to extent expected   4        3        2        1
8. What other topics are of interest to you?  


Due to the content of this activity, I will change my practice patterns by:

Review my organization’s coverage of NSCLC
Provide treatment guidelines to providers
My practice patterns will not change
Other    Specify:

Continuing education implies quality improvement in behavior. As part of our quality improvement process, NAMCP/AAMCN will contact you 6 months from your post test submission to monitor change.
Name:  
Profession: MD  DO  RN  CMCN  Other
Company:  
Mailing Address:  
City, State, Zip:  
Phone:  
Fax:  
Email:  
Heard About Activity By: eNews  Colleague  Internet    JMCM Article
 Email   Phone
 
Send my certificate by: U.S. Mail             Email
 

Help us cut down spam.

Type the number 411 into
the following box (Required)